Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: JCSM Rapid Commun. 2022 Oct 14;6(1):18–25. doi: 10.1002/rco2.72

Table 3:

12 Month Treatment Effects on Body Composition Metrics.

Outcome Measures Risedronate Placebo
n 12-Month 12-Month Δ n 12-Month 12-Month Δ p
Body mass (kg) 5 101.7 (95.4, 108.0) −13.9 (−20.2, −7.6) 9 95.6 (90.9, 100.3) −20.0 (−24.6, −15.3) .121
BMI (kg/m2) 5 38.4 (35.9, 40.8) −4.9 (−7.4, −2.5) 9 36.1 (34.3, 37.9) −7.2 (−9.0, −5.4) .130
DXA-Acquired Measures
Total Fat Mass (kg) 5 47.0 (41.4, 52.6) −11.0 (−16.6, −5.4) 9 42.1 (38.0, 46.2) −15.9 (−20.0, −11.7) .163
Percent Fat Mass (%) 5 46.7 (42.7, 50.7) −3.4 (−7.4, 0.6) 9 43.2 (40.1, 46.2) −6.9 (−10.0, −3.9) .162
Total Lean Mass (kg) 5 51.8 (50.0, 53.5) −1.9 (−3.6, −0.1) 9 50.2 (48.8, 51.5) −3.5 (−4.8, −2.1) .141
Appendicular Lean Mass (kg) 5 23.9 (22.8, 24.9) −0.5 (−1.5, 0.6) 9 21.5 (20.7, 22.3) −2.9 (−3.6, −2.1) .001
Appendicular Lean Mass Index (kg/m2) 5 9.0 (8.6, 9.4) −0.1 (−0.5, 0.3) 9 8.0 (7.7, 8.3) −1.0 (−1.3, −0.7) .001
Lean-to-Fat Ratio 5 1.2 (1.0, 1.4) 0.2 (0.0, 0.4) 9 1.3 (1.1, 1.4) 0.3 (0.2, 0.5) .342
CT Acquired Measures
Total Trunk Muscle CSA (cm2) 4 129.2 (122.4, 135.9) −7.9 (−14.6, −1.1) 8 122.2 (116.9, 127.6) −14.8 (−20.1, −9.5) .111
Skeletal Muscle Index (cm2/m2) 4 50.5 (47.8, 53.1) −3.1 (−5.7, −0.4) 8 47.7 (45.7, 49.8) −5.8 (−7.9, −3.7) .111
Total Trunk Muscle Attenuation (HU) 4 34.9 (31.9, 37.9) −4.2 (−7.2, −1.2) 8 37.0 (34.8, 39.3) −2.1 (−4.4, 0.1) .259
Mid-Thigh Muscle CSA (cm2) 4 102.8 (95.8, 109.8) −2.1 (−9.0, 4.9) 8 95.0 (89.2, 100.9) −9.8 (−15.6, −4.0) .095
Mid-Thigh Muscle Attenuation (HU) 4 36.4 (34.2, 38.7) −1.3 (−3.6, 1.0) 8 38.4 (36.5, 40.3) 0.6 (−1.3, 2.5) .183

Group treatment effect and difference estimates from a mixed model using contrast statements at 12 months adjusted for baseline values of each outcome

BMI: Body Mass Index; CSA: Cross-Sectional Area; HU: Hounsfield Units